Form 4: Serina Therapeutics Director Acquires Stock Options
SEC Filing
Karen J. Wilson, a director of Serina Therapeutics, Inc., acquired stock options for 40,000 shares on January 14, 2025.
Summary
- On January 14, 2025, Karen J. Wilson, a director of Serina Therapeutics, Inc., filed a Form 4.
- The filing reports the acquisition of stock options representing the right to buy 40,000 shares of Serina Therapeutics common stock.
- The exercise price of these options is $4.90 per share.
- The options vest in equal yearly installments over three years, starting on the first anniversary of the grant date, contingent upon continued service to the Issuer.
- The options expire on January 13, 2035.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing, so the sentiment is neutral. It reflects a director's acquisition of stock options, which is neither inherently positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, regarding the company's securities.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 01/14/2025 | Date of transaction: Director acquired stock options. |
| 01/14/2026 | First vesting date of the stock options. |
| 01/13/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.